Evidence map›Paper›PMID 32018062›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2020

A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease.

Joanne Kurtzberg, Hisham Abdel-Azim, Paul Carpenter, Sonali Chaudhury, Biljana Horn, Kris Mahadeo, Eneida Nemecek, Steven Neudorf, Vinod Prasad, Susan Prockop and 7 more

2 registry-linked trialsOpen access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 129 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed, 2 pooled it
14.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02336230 phase3completednot on this map

A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD

TypeinterventionalSponsorMesoblast, Inc.Ran2015 to 2018Enrolled55ConditionsGrade B aGVHD, Grade C aGVHD, Grade D aGVHDArmsremestemcel-L
NCT07576699 phase1 / phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)

TypeinterventionalSponsorCellenkos, Inc.Ran2026 to 2029Enrolled12ConditionsSteroid Refractory Graft Versus Host DiseaseArmsCK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)
3 · Its place in the literature

Who cites it

129 citing papers in PubMed, 2 syntheses or guidelines pooled it, 180 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Baseline CD4Journal of blood medicine · 2025
    Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. [Research advances in mesenchymal stem cell therapy for graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

69 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 1 country.

Joanne KurtzbergDuke University Medical Center, Durham, North Carolina. Electronic address: joanne.kurtzberg@duke.edu.
Hisham Abdel-AzimChildren's Hospital of Los Angeles, Los Angeles, California.
Paul CarpenterFred Hutchinson Cancer Research Center, Seattle, Washington.
Sonali ChaudhuryAnn & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Biljana HornUCSF Benioff Children's Hospital, San Francisco, California.
Kris MahadeoAlbert Einstein College of Medicine, New York, New York.
Eneida NemecekOregon Health & Science University, Portland, Oregon.
Steven NeudorfChildren's Hospital of Orange County, Orange, California.
Vinod PrasadDuke University Medical Center, Durham, North Carolina.
Susan ProckopMSK Kids (formerly Memorial Sloan Kettering Cancer Center), New York, NY.
Troy QuiggTexas Transplant Institute, San Antonio, Texas.
Prakash SatwaniColumbia University Medical Center, New York, New York.
Annie ChengMesoblast, Inc., New York, NY.
Elizabeth BurkeMesoblast, Inc., New York, NY.
Jack HayesMesoblast, Inc., New York, NY.
Donna SkerrettMesoblast, Inc., New York, NY.
MSB-GVHD001/002 Study Group
Mesoblast (United States) · USDuke Medical Center · USAlbert Einstein College of Medicine · USChildren's Hospital of Los Angeles · USChildren's Hospital of Orange County · USCHRISTUS Transplant Institute · USColumbia University Irving Medical Center · USFred Hutch Cancer Center · USLurie Children's Hospital · USMemorial Sloan Kettering Cancer Center · USOregon Health & Science University · USUCSF Benioff Children's Hospital · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Steroid-refractory acute graft-versus-host disease (SR-aGVHD) following hematopoietic cell transplantation (HSCT) is associated with poor clinical outcomes. Currently, there are no safe and effective therapies approved for use in the pediatric population under the age of 12 years. Accordingly, there is an urgent need for new treatments that are safe, well tolerated, and effective in managing this debilitating and potentially fatal complication of HSCT. In early phase clinical trials, mesenchymal stromal cells (MSCs) have demonstrated efficacy in the treatment of acute GVHD (aGVHD) in pediatric patients. We now report the results of a phase 3, prospective, single-arm, multicenter study (NCT02336230) in 54 children with primary SR-aGVHD who were naive to other immunosuppressant therapies for aGVHD treated with MSC product (remestemcel-L) dosed at 2 × 10

Indexed as

Graft vs Host DiseaseMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAcute DiseaseAdultChildHumansProspective StudiesSteroidsSteroidsAcute graft-versus-host diseaseAllogeneicHematopoietic stem cell transplantationMesenchymal stromal cellsRemestemcel-LSteroid

Identifiers

PMID32018062
PMCPMC8322819
OpenAlexW3004044398

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.